NewCardio, Inc. (NWCI)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NewCardio, Inc. (NWCI) trades at $0.00 with AI Score 58/100 (Hold). NewCardio, Inc. focuses on developing and commercializing non-invasive cardiac diagnostic solutions. Market cap: 4K, Sector: Healthcare.
Last analyzed: Mar 3, 2026NewCardio, Inc. (NWCI) Healthcare & Pipeline Overview
NewCardio, Inc. pioneers non-invasive cardiac diagnostics with its proprietary software platform, offering real-time 3D analysis of heart activity and cardiac safety assessments, positioning it as a key player in the evolving cardiovascular disease management landscape despite its micro-cap status.
Investment Thesis
Investing in NewCardio, Inc. presents a speculative opportunity within the cardiac diagnostics sector. The company's focus on innovative, non-invasive solutions for CVD diagnosis and cardiac safety assessment positions it for potential growth, particularly with products like QTinno and CardioBip. Key value drivers include successful commercialization of these technologies and strategic partnerships within the pharmaceutical industry for cardiac safety assessments. While the company's negative P/E ratio and significant negative profit margin of -4466.2% indicate financial challenges, successful development and adoption of their technology could drive significant revenue growth. Investors should closely monitor the company's progress in securing regulatory approvals and establishing market presence. The high beta of -120.60 suggests extreme volatility.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 40.8% indicates potential profitability if sales volume increases.
- Developing QTinno, an automated cardiac safety solution, addresses a critical need in drug development.
- CardioBip mobile ECG system offers a convenient solution for remote cardiac monitoring.
- Focus on non-invasive diagnostics aligns with the trend towards less invasive medical procedures.
- Proprietary software platform provides a foundation for future product development and innovation.
Competitors & Peers
Strengths
- Proprietary software platform for cardiac diagnostics.
- Focus on non-invasive solutions.
- Developing innovative products like QTinno and CardioBip.
- Expertise in cardiac safety assessment.
Weaknesses
- Limited financial resources.
- Small number of employees.
- Negative profit margin.
- Dependence on successful commercialization of new products.
Catalysts
- Upcoming: Regulatory approval of QTinno for automated cardiac safety assessment.
- Upcoming: Commercial launch of CardioBip for remote patient monitoring.
- Ongoing: Strategic partnerships with pharmaceutical companies for cardiac safety assessments.
- Ongoing: Development and launch of my3KG for advanced cardiac analysis.
Risks
- Potential: Dilution of existing shareholders through future equity offerings.
- Ongoing: Limited financial resources and potential need for additional funding.
- Potential: Competition from larger, more established companies.
- Potential: Regulatory setbacks or delays in product approvals.
- Ongoing: Dependence on key personnel and potential loss of expertise.
Growth Opportunities
- Expansion of QTinno in pharmaceutical cardiac safety: QTinno, an automated cardiac safety solution, can be expanded within the pharmaceutical industry. The market for cardiac safety assessment during drug development is substantial, driven by regulatory requirements and the need to prevent drug-induced cardiac arrhythmias. Success in this area could generate recurring revenue streams through partnerships with pharmaceutical companies. Timeline: Ongoing.
- Commercialization of CardioBip for remote patient monitoring: CardioBip, a mobile ECG transtelephonic system, offers potential for remote patient monitoring, especially for individuals at risk of cardiac events. The market for remote cardiac monitoring is expanding due to the increasing adoption of telehealth and the need for cost-effective healthcare solutions. Successful commercialization of CardioBip could provide a recurring revenue stream through subscription-based services. Timeline: 1-2 years.
- Development and launch of my3KG for advanced cardiac analysis: my3KG, a software application to assess cardiac electrical activity in time and space, can provide advanced cardiac analysis, potentially improving diagnostic accuracy. The market for advanced cardiac diagnostics is growing, driven by the need for more precise and personalized treatment strategies. Timeline: 2-3 years.
- Strategic partnerships with healthcare providers: Collaborating with hospitals and clinics to integrate NewCardio's diagnostic solutions into their workflows can drive adoption and generate revenue. Strategic partnerships can provide access to a broader patient base and facilitate the integration of NewCardio's technology into existing healthcare systems. Timeline: Ongoing.
- Geographic expansion into international markets: Expanding into international markets, particularly in regions with growing healthcare infrastructure and increasing prevalence of cardiovascular diseases, can drive revenue growth. International expansion requires adapting to local regulatory requirements and healthcare practices, but it can provide access to new customer segments and revenue streams. Timeline: 3-5 years.
Opportunities
- Growing market for non-invasive cardiac monitoring.
- Increasing demand for cardiac safety assessment in drug development.
- Expansion into remote patient monitoring.
- Strategic partnerships with healthcare providers and pharmaceutical companies.
Threats
- Competition from established players in the medical device industry.
- Regulatory hurdles and approval processes.
- Technological obsolescence.
- Economic downturn affecting healthcare spending.
Competitive Advantages
- Proprietary software platform technology.
- Patents and intellectual property related to cardiac diagnostic methods.
- Expertise in non-invasive cardiac diagnostics.
- Established relationships with key opinion leaders in cardiology.
About NWCI
Founded in 2004 and based in Branchburg, New Jersey, NewCardio, Inc. is a cardiac diagnostic and services company dedicated to the research, development, and commercialization of proprietary software platform technology solutions. The company addresses the critical need for non-invasive diagnosis and monitoring of cardiovascular disease (CVD) and cardiac safety assessment of drugs under development. NewCardio's core technology platform provides real-time and 3-D analysis of the heart's electrical activity, utilizing standard 12-lead electrocardiogram (ECG) electrodes to detect activity at the body surface. Their developing product pipeline includes QTinno, an automated cardiac safety solution designed to replace manual methodologies with algorithms for ECG analysis and reporting. Another key product is CardioBip, a mobile ECG transtelephonic system that comprises a mobile ECG recording and transmitting device, coupled with web-enabled software for data processing and analysis. Additionally, NewCardio is developing my3KG, a software application aimed at assessing cardiac electrical activity in both time and space, further expanding its diagnostic capabilities. NewCardio aims to improve the accuracy and efficiency of cardiac diagnostics, contributing to better patient outcomes in the management of cardiovascular diseases.
What They Do
- Develop proprietary software platform technology solutions for cardiac diagnostics.
- Offer non-invasive diagnosis and monitoring of cardiovascular disease (CVD).
- Provide cardiac safety assessment of drugs under development.
- Offer real-time and 3-D analysis of the heart's electrical activity.
- Develop QTinno, an automated cardiac safety solution.
- Develop CardioBip, a mobile ECG transtelephonic system.
- Develop my3KG, a software application to assess cardiac electrical activity.
Business Model
- Software licensing for QTinno to pharmaceutical companies.
- Sales of CardioBip mobile ECG devices.
- Subscription-based services for remote cardiac monitoring.
- Partnerships with healthcare providers for diagnostic services.
Industry Context
NewCardio operates within the medical device industry, specifically focusing on cardiac diagnostics. The market for non-invasive cardiac monitoring is growing, driven by an aging population and increasing prevalence of cardiovascular diseases. Competition includes established players like BBAL and EVARF, as well as companies focused on specific segments of the cardiac diagnostics market. NewCardio's success depends on its ability to differentiate its technology and secure partnerships with healthcare providers and pharmaceutical companies. The industry is subject to regulatory scrutiny and technological advancements, requiring continuous innovation and adaptation.
Key Customers
- Pharmaceutical companies requiring cardiac safety assessments.
- Hospitals and clinics using cardiac diagnostic tools.
- Patients requiring remote cardiac monitoring.
- Cardiologists and other healthcare professionals.
Financials
Chart & Info
NewCardio, Inc. (NWCI) stock price: $0.00 (+0.00, +0.00%)
Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Nov 26, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NWCI.
Price Targets
Wall Street price target analysis for NWCI.
MoonshotScore
What does this score mean?
The MoonshotScore rates NWCI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
NWCI OTC Market Information
NWCI trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
NewCardio, Inc. Stock: Key Questions Answered
What does NewCardio, Inc. (NWCI) do?
NewCardio, Inc. (NWCI) is a cardiac diagnostic and services company that develops and commercializes proprietary software platform technology solutions. The company focuses on non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. Their key products include QTinno, an automated cardiac safety solution, and CardioBip, a mobile ECG transtelephonic system, aiming to improve the accuracy and efficiency of cardiac diagnostics.
Is NWCI stock worth researching?
Evaluating whether NWCI stock is worth researching requires careful consideration. The company's innovative technology in cardiac diagnostics and potential for growth in the remote patient monitoring market are positive factors. However, the negative P/E ratio and significant negative profit margin of -4466.2% indicate financial challenges. Investors should weigh the potential for future revenue growth against the risks associated with a micro-cap company with limited resources and high volatility, as reflected in its beta of -120.60.
What are the risks of investing in NWCI?
Investing in NWCI carries several risks. The company's limited financial resources and negative profit margin raise concerns about its ability to sustain operations and fund future growth. There is a potential risk of dilution through future equity offerings. The company also faces competition from larger, more established players in the medical device industry, as well as regulatory hurdles and potential delays in product approvals. Dependence on key personnel also poses a risk.
What catalysts could move NWCI stock?
Several catalysts could potentially move NWCI stock. Regulatory approval of QTinno for automated cardiac safety assessment would be a significant milestone, as would the commercial launch of CardioBip for remote patient monitoring. Strategic partnerships with pharmaceutical companies for cardiac safety assessments could also drive revenue growth and investor interest. Positive results from the development and launch of my3KG for advanced cardiac analysis could further enhance the company's prospects.
What is NWCI stock price target?
As of March 3, 2026, there is no available analyst consensus or established price target for NWCI stock due to its micro-cap status and limited coverage. Determining a fair value estimate would require a detailed analysis of the company's future revenue potential, profitability, and cash flow projections, considering the inherent risks and uncertainties associated with its stage of development and market position.
What are the key factors to evaluate for NWCI?
NewCardio, Inc. (NWCI) currently holds an AI score of 58/100, indicating moderate score. Key strength: Proprietary software platform for cardiac diagnostics.. Primary risk to monitor: Potential: Dilution of existing shareholders through future equity offerings.. This is not financial advice.
How frequently does NWCI data refresh on this page?
NWCI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NWCI's recent stock price performance?
Recent price movement in NewCardio, Inc. (NWCI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary software platform for cardiac diagnostics.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited available data.
- Financial metrics may not be fully up-to-date.
- Investment in micro-cap stocks involves significant risk.